
FDA Releases Draft Guidance on Using the Inactive Ingredient Database
The draft guidance provides industry with a guide for using the database to assist in the development of drug products.
On July 10, 2019, FDA published
The guidance also describes how the agency uses the IID to support the safety of inactive ingredients. It describes the structure of the IID, the process for adding ingredients to the IID, and how information is presented in the database, which gives users a better understanding of how to use the information.
The IDD lists information on inactive ingredients used in FDA-approved drug products. Once an inactive ingredient is used in an approved drug for a specific route of administration it is not considered novel; therefore, the ingredient may not require extensive review by the agency the next time it is used in a new product.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.